HUTCHMED (China) Limited (HK:0013) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HUTCHMED (China) Limited has announced promising results from the SAVANNAH Phase II trial, where the combination of TAGRISSO® and ORPATHYS® showed a significant response rate in patients with certain types of lung cancer resistant to existing treatments. This combination therapy targets MET-driven resistance, a common issue in patients with EGFR-mutated non-small cell lung cancer, and could represent a new treatment option for those who have exhausted other avenues.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.